+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Cystic Fibrosis Market Research Report by Drug Class - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 4829814
  • Report
  • June 2020
  • Region: Global
  • 225 pages
  • 360iResearch™
until Dec 31st 2020

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Cystic Fibrosis Market to Grow USD 21,609.84 Million by 2025, at a CAGR of 12.64%


  • AbbVie Inc.
  • AlgiPharma AS
  • Allergan plc
  • AstraZeneca plc
  • Celtaxsys, Inc.
  • Elucigene Diagnostics
  • MORE
The Global Cystic Fibrosis Market is expected to grow from USD 10,574.80 Million in 2019 to USD 21,609.84 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 12.64%.

Market Segmentation & Coverage:

This research report categorizes the Cystic Fibrosis to forecast the revenues and analyze the trends in each of the following sub-markets:

On the basis of Drug Class, the Cystic Fibrosis Market is examined across Bronchodilators, CFTR Modulators, Mucolytics, and Pancreatic Enzyme Supplements.

On the basis of Route of Administration, the Cystic Fibrosis Market is examined across Inhaled Drugs and Oral Drugs.

On the basis of Geography, the Cystic Fibrosis Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is examined across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is examined across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is examined across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cystic Fibrosis Market including AbbVie Inc., Advanced Inhalation Therapies (AIT) Ltd., Alcresta Therapeutics, Inc., AlgiPharma AS, Allergan plc, AstraZeneca plc, Celtaxsys, Inc., Elucigene Diagnostics, F. Hoffmann-La Roche AG, Galapagos NV, Gilead Sciences, Inc., NovaBiotics Ltd, Novartis International AG, Teva Pharmaceutical Industries Ltd, and Vertex Pharmaceuticals, Inc..

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cystic Fibrosis Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cystic Fibrosis Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cystic Fibrosis Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cystic Fibrosis Market?
4. What is the competitive strategic window for opportunities in the Global Cystic Fibrosis Market?
5. What are the technology trends and regulatory frameworks in the Global Cystic Fibrosis Market?
6. What are the modes and strategic moves considered suitable for entering the Global Cystic Fibrosis Market?
Note: Product cover images may vary from those shown


  • AbbVie Inc.
  • AlgiPharma AS
  • Allergan plc
  • AstraZeneca plc
  • Celtaxsys, Inc.
  • Elucigene Diagnostics
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
2.3.1. Competitive Strategic Window

3. Executive Summary
3.1. Market Outlook
3.2. Drug Class Outlook
3.3. Route of Administration Outlook
3.4. Geography Outlook
3.5. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cystic Fibrosis Market, By Geography

5. Market Dynamics
5.1. Introduction
5.1.1. Drivers Rising prevalence of Cystic Fibrosis & improved diagnostic technologies Increasing global awareness for Cystic Fibrosis Research & development activities and robust drug development pipeline Favorable initiatives are taken by NGOs, government, and private companies
5.1.2. Restraints Expiring patents and generic drugs Increase in genetic mutation rate
5.1.3. Opportunities Increasing demand from emerging economies Growing strategic collaborations, merger, and acquisition
5.1.4. Challenges High cost involved in treatment and complicated pathophysiology

6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations

7. Global Cystic Fibrosis Market, By Drug Class
7.1. Introduction
7.2. Bronchodilators
7.3. CFTR Modulators
7.4. Mucolytics
7.5. Pancreatic Enzyme Supplements

8. Global Cystic Fibrosis Market, By Route of Administration
8.1. Introduction
8.2. Inhaled Drugs
8.3. Oral Drugs

9. Americas Cystic Fibrosis Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Cystic Fibrosis Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. South Korea
10.10. Thailand

11. Europe, Middle East & Africa Cystic Fibrosis Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding

13. Company Usability Profiles
13.1. AbbVie Inc.
13.2. Advanced Inhalation Therapies (AIT) Ltd.
13.3. Alcresta Therapeutics, Inc.
13.4. AlgiPharma AS
13.5. Allergan plc
13.6. AstraZeneca plc
13.7. Celtaxsys, Inc.
13.8. Elucigene Diagnostics
13.9. F. Hoffmann-La Roche AG
13.10. Galapagos NV
13.11. Gilead Sciences, Inc.
13.12. NovaBiotics Ltd
13.13. Novartis International AG
13.14. Teva Pharmaceutical Industries Ltd
13.15. Vertex Pharmaceuticals, Inc.

14. Appendix
14.1. Discussion Guide
14.2. Edition Details
14.3. License Details
14.4. Pricing Details
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Advanced Inhalation Therapies (AIT) Ltd.
  • Alcresta Therapeutics, Inc.
  • AlgiPharma AS
  • Allergan plc
  • AstraZeneca plc
  • Celtaxsys, Inc.
  • Elucigene Diagnostics
  • F. Hoffmann-La Roche AG
  • Galapagos NV
  • Gilead Sciences, Inc.
  • NovaBiotics Ltd
  • Novartis International AG
  • Teva Pharmaceutical Industries Ltd
  • Vertex Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown